{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:14:10Z","timestamp":1775477650278,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Immunosuppressive chemotherapy increase the risk of vaccine-preventable infectious diseases in children; nevertheless, chemotherapy may result in delay or miss updated immunization schedules. The predictable antibody waning after incomplete primary immunization series may be intensified at the end of chemotherapy. This study aimed to investigate post-chemotherapy vaccine immunity waning at the end of immunosuppressive therapy in children with malignancy and hematologic disorders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Children with malignancies and hematologic disorders including chronic immune thrombocytopenic purpura (ITP) younger than 18\u00a0years old were enrolled from September 2015 to August 2019. Eligible patients who completed their treatment protocol for at least 6\u00a0months were recruited. The patient information, including sex, age at the date of diagnosis, number of chemotherapy sessions, underlying disease, and vaccination history, was taken by chart review using predefined questionnaires. The patient\u2019s blood samples were obtained, and serum IgG antibody titer checked against diphtheria, tetanus, hepatitis B virus (HBV), mumps, measles, and rubella (MMR) were measured by enzyme-linked immunosorbent assay (ELISA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>110 children receiving immunosuppressive chemotherapy were recruited. Forty-four (40%) of the children tested were girls and 66 (60%) were boys. The mean age of patients was 5.5\u00a0years with a range of 2 to 13\u00a0years. Of 110 studied children, 27.3% were seronegative for all antibodies. On average, patients undergo 19 episodes of chemotherapy. The mean chemotherapy sessions were significantly greater in children who were seronegative for all tested antibodies (mean: 36.2, 95% CI 33.16 to 39.24, p-value\u2009&lt;\u20090.001). No statistically significant differences were observed regarding the patient\u2019s sex and age between the seropositive and seronegative groups (p-value 0.513 and 0.060, respectively). Based on Poisson regression model analysis, the female gender was associated with 37% lower odds of seronegativity (incidence rate ratio (IIR): 0.63; [95% conf. interval: 0.39 to 1.01, p-value: 0.55]), while chemotherapy sessions 30 or more was associated with significant odds of seronegativity for all tested vaccines (IIR: 25.41; [95% conf. interval: 6.42 to 100.57, p-value\u2009&lt;\u20090.001]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results reemphasized planned catchup immunization in children undergoing immunosuppressive chemotherapy for malignancy, especially against tetanus, diphtheria, and hepatitis B at least 6\u00a0months after the end of chemotherapy sessions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07647-1","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T14:08:03Z","timestamp":1659017283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antibody waning after immunosuppressive chemotherapy and immunomodulators, re-immunization considerations in pediatric patients with malignancy and chronic immune thrombocytopenic purpura"],"prefix":"10.1186","volume":"22","author":[{"given":"Babak","family":"Abdolkarimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Amanati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Molavi Vardanjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safura\u200f","family":"\u200fJamshidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seid Amir Pasha","family":"Tabaeian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"issue":"1","key":"7647_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5152\/eurasianjmed.2020.20047","volume":"53","author":"P Yilmazbas","year":"2021","unstructured":"Yilmazbas P, Sen HS, Ocak S. Revaccination in pediatric oncology patients: one center experience. Eurasian J Med. 2021;53(1):5.","journal-title":"Eurasian J Med"},{"issue":"8","key":"7647_CR2","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1016\/S2352-3018(16)30010-8","volume":"3","author":"T Bunupuradah","year":"2016","unstructured":"Bunupuradah T, Kiertiburanakul S, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N, Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV. 2016;3(8):e343\u201350.","journal-title":"Lancet HIV"},{"issue":"3","key":"7647_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.phoj.2020.06.004","volume":"5","author":"NR Moulik","year":"2020","unstructured":"Moulik NR, Arora RS. Immunisation in children with cancer treated with standard dose chemotherapy-review of evidence. Pediatric Hematol Oncol J. 2020;5(3):89\u201395.","journal-title":"Pediatric Hematol Oncol J"},{"issue":"3","key":"7647_CR4","first-page":"228","volume":"12","author":"AK Shetty","year":"2012","unstructured":"Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J. 2012;12(3):228\u201343.","journal-title":"Ochsner J"},{"issue":"3","key":"7647_CR5","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44\u2013100.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"7647_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00043426-199809000-00008","volume":"20","author":"MM Mustafa","year":"1998","unstructured":"Mustafa MM, Buchanan GR, Winick NJ, McCracken GH, Tkaczewski I, Lipscomb M, Ansari Q, Agopian MS. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol. 1998;20(5):451\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"7647_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s13312-019-1678-0","volume":"56","author":"NR Moulik","year":"2019","unstructured":"Moulik NR, Mandal P, Chandra J, Bansal S, Jog P, Sanjay S, Shah N, Arora RS. Immunization of children with cancer in india treated with chemotherapy\u2014consensus guideline from the pediatric hematology-oncology chapter and the advisory committee on vaccination and immunization practices of the indian academy of pediatrics. Indian Pediatr. 2019;56(12):1041\u20138.","journal-title":"Indian Pediatr"},{"issue":"4","key":"7647_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das RK, Vernau L, Grupp SA, Barrett DM. Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9(4):492\u20139.","journal-title":"Cancer Discov"},{"key":"7647_CR9","unstructured":"Research Ethics Certificate. https:\/\/www.ethics.research.ac.ir\/form\/slbgy6i4nzc8qr.pdf."},{"issue":"7","key":"7647_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3109\/08880018.2013.877111","volume":"31","author":"L Koochakzadeh","year":"2014","unstructured":"Koochakzadeh L, Khosravi MH, Pourakbari B, Hosseinverdi S, Aghamohammadi A, Rezaei N. Assessment of immune response following immunization with DTP\/Td and MMR vaccines in children treated for acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31(7):656\u201363.","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"7647_CR11","first-page":"635","volume":"101","author":"M Zignol","year":"2004","unstructured":"Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D\u2019Elia R, Zanesco L, Cesaro S. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer Interdiscipl Int J Am Cancer Soc. 2004;101(3):635\u201341.","journal-title":"Cancer Interdiscipl Int J Am Cancer Soc"},{"issue":"10","key":"7647_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/sj.leu.2404326","volume":"20","author":"CM van Tilburg","year":"2006","unstructured":"van Tilburg CM, Sanders EA, Rovers MM, Wolfs T, Bierings M. Loss of antibodies and response to (re-) vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia. 2006;20(10):1717\u201322.","journal-title":"Leukemia"},{"issue":"4","key":"7647_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2352-4642(20)30312-6","volume":"5","author":"GM Guilcher","year":"2021","unstructured":"Guilcher GM, Rivard L, Huang JT, Wright NA, Anderson L, Eissa H, Pelletier W, Ramachandran S, Schechter T, Shah AJ. Immune function in childhood cancer survivors: a Children\u2019s Oncology Group review. Lancet Child Adolesc Health. 2021;5(4):284\u201394.","journal-title":"Lancet Child Adolesc Health"},{"issue":"39","key":"7647_CR14","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","volume":"36","author":"M van Aalst","year":"2018","unstructured":"van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis. Vaccine. 2018;36(39):5832\u201345.","journal-title":"Vaccine"},{"issue":"2","key":"7647_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3324\/haematol.2010.032664","volume":"96","author":"H de Lavallade","year":"2011","unstructured":"de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96(2):307.","journal-title":"Haematologica"},{"issue":"11","key":"7647_CR16","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","volume":"122","author":"I Nazi","year":"2013","unstructured":"Nazi I, Kelton JG, Larch\u00e9 M, Snider DP, Heddle NM, Crowther MA, Cook RJ, Tinmouth AT, Mangel J, Arnold DM. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946\u201353.","journal-title":"Blood"},{"issue":"6","key":"7647_CR17","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","volume":"100","author":"LE van der Kolk","year":"2002","unstructured":"van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257\u20139.","journal-title":"Blood"},{"issue":"12","key":"7647_CR18","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1080\/14760584.2016.1193438","volume":"15","author":"DR Cheng","year":"2016","unstructured":"Cheng DR, Barton R, Greenway A, Crawford NW. Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. Expert Rev Vaccines. 2016;15(12):1567\u201374.","journal-title":"Expert Rev Vaccines"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07647-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T14:08:15Z","timestamp":1659017295000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07647-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7647"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07647-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was found to be in compliance with the national norms and regulations for conducting medical research in Iran as well as the ethical principles. The study was approved by \u201c<i>Iran National Committee for Ethics in Biomedical Research<\/i>\u201d with approval ID: IR.LUMS.REC.1398.170 []. All of the precipitants or their parents were informed about this study, and the parents who allowed their children to be tested and signed the consent form were included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors do not have any financial or other relationships, which could regard as a conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"657"}}